ECOG-ACRIN is now enrolling ComboMATCH-E5 Treatment Trial for patients with advanced Solid Tumors

ECOG-ACRIN is now enrolling ComboMATCH-E5 Treatment Trial for patients with advanced Solid Tumors

ECOG-ACRIN Cancer Research Group shared a post on X:

“ComboMATCH Treatment Trial E5, led by Kristen Spencer of Perlmutter Cancer Center at NYU Langone Health and Dustin Deming of UW Health | Carbone Cancer Center, is a randomized phase 2 study of sotorasib with or without panitumumab in advanced Solid Tumors.

Learn more here.”